Japanese launch for once-daily tacrolimus
This article was originally published in Scrip
Astellaswill launch Graceptor, its once-daily formulation of the immunosuppressant tacrolimus, in Japan on October 28th. The oral product is indicated for organ rejection in kidney, liver, heart, lung and pancreas transplants, and graft rejection and graft-versus-host disease in bone marrow transplantation. It is already marketed (as Advagraf) in 19 other countries but has faced regulatory difficulties in the US, where the patent for Prograf, the standard release product, expired in April. Japanese pricing authorities predict peak annual reimbursement level sales of Graceptor will reach around ¥16 billion ($171.6 million).
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.